Literature DB >> 30119060

Effectiveness of robot-assisted gait training on motor impairments in people with Parkinson's disease: a systematic review and meta-analysis.

Mohammad Alwardat1,2, Mohammad Etoom3, Salameh Al Dajah3, Tommaso Schirinzi1,4, Giulia Di Lazzaro1, Paola Sinibaldi Salimei5, Nicola Biagio Mercuri1,2,6, Antonio Pisani1,2,6.   

Abstract

The aim of this systematic review and meta-analysis was to evaluate the effectiveness of robot-assisted gait training (RAGT) on motor impairments in people with Parkinson's disease (PD). A computer-based systematic literature search was performed in six databases according to PRISMA guidelines. Randomized controlled trials (RCTs) that assessed the effects of RAGT on motor impairments in people with PD were included. GRADE approach and PEDro scale were used to determine the studies' quality of evidence. Meta-analyses were performed by calculating the weighted mean difference (WMD) at 95% confidence interval. Seven RCTs (PEDro: 5-8) met the inclusion criteria for systematic review and meta-analyses. The meta-analysis showed significant improvement on Unified Parkinson Disease Rating Scale Part III after intervention [WMD=3.292; 95% confidence interval (CI)=1.378-5.207; P=0.000], and after 1-month follow-up (WMD=5.512; 95% CI=2.396-8.629; P=0.001). Stride length (WMD=9.283; 95% CI=7.153-11.414; P=0.00) and gait speed (WMD=0.166; 95% CI=-0.090 to 0.243; P=0.000) showed significant improvements after RAGT. Balance as measured by Berg Balance Scale was improved significantly after intervention (WMD=3.87; 95% CI=0.374-6.735; P=0.029) and at 1-month follow-up (WMD=3.87; 95% CI=1.324-6.413; P=0.002). The pooled analysis did not detect any significant changes regarding stride time, cadence and functional balance scales. GRADE level of evidence ranged between high and low. The RAGT showed better outcomes than conventional interventions on some motor aspects in PD. However, RAGT did not seem superior to control interventions. Further RCTs that examine the effect of RAGT on more specific outcomes and at different medication statuses are required.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30119060     DOI: 10.1097/MRR.0000000000000312

Source DB:  PubMed          Journal:  Int J Rehabil Res        ISSN: 0342-5282            Impact factor:   1.479


  6 in total

Review 1.  Settings matter: a scoping review on parameters in robot-assisted gait therapy identifies the importance of reporting standards.

Authors:  Florian van Dellen; Rob Labruyère
Journal:  J Neuroeng Rehabil       Date:  2022-04-22       Impact factor: 5.208

2.  The Category of Conventional Physiotherapy: The Case of Parkinson's Disease Guidelines.

Authors:  Martina Hoskovcová; Evžen Růžička; Ota Gál
Journal:  J Pers Med       Date:  2022-04-30

3.  Biofeedback Core Exercise Using Hybrid Assistive Limb for Physical Frailty Patients With or Without Parkinson's Disease.

Authors:  Naoya Kotani; Takashi Morishita; Aya Yatsugi; Shinsuke Fujioka; Satoshi Kamada; Etsuji Shiota; Yoshio Tsuboi; Tooru Inoue
Journal:  Front Neurol       Date:  2020-04-09       Impact factor: 4.003

4.  Rehabilitation of older people with Parkinson's disease: an innovative protocol for RCT study to evaluate the potential of robotic-based technologies.

Authors:  Roberta Bevilacqua; Elvira Maranesi; Mirko Di Rosa; Riccardo Luzi; Elisa Casoni; Nadia Rinaldi; Renato Baldoni; Fabrizia Lattanzio; Valentina Di Donna; Giuseppe Pelliccioni; Giovanni Renato Riccardi
Journal:  BMC Neurol       Date:  2020-05-13       Impact factor: 2.474

5.  Analysis of Gait for Disease Stage in Patients with Parkinson's Disease.

Authors:  Mᵃ Helena Vila; Rocío Pérez; Irimia Mollinedo; José Mᵃ Cancela
Journal:  Int J Environ Res Public Health       Date:  2021-01-15       Impact factor: 3.390

Review 6.  Detection and assessment of Parkinson's disease based on gait analysis: A survey.

Authors:  Yao Guo; Jianxin Yang; Yuxuan Liu; Xun Chen; Guang-Zhong Yang
Journal:  Front Aging Neurosci       Date:  2022-08-03       Impact factor: 5.702

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.